132 related articles for article (PubMed ID: 25389779)
1. Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis.
Maasoumy B; Hunyady B; Calvaruso V; Makara M; Vermehren J; Haragh A; Susser S; Bremer B; Cloherty G; Manns MP; Craxì A; Wedemeyer H; Sarrazin C
PLoS One; 2014; 9(11):e110857. PubMed ID: 25389779
[TBL] [Abstract][Full Text] [Related]
2. Impact of HCV kinetics on treatment outcome differs by the type of real-time HCV assay in NS3/4A protease inhibitor-based triple therapy.
Ogawa E; Furusyo N; Murata M; Hayashi T; Shimizu M; Mukae H; Toyoda K; Hotta T; Uchiumi T; Hayashi J
Antiviral Res; 2016 Feb; 126():35-42. PubMed ID: 26692214
[TBL] [Abstract][Full Text] [Related]
3. Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.
Inoue T; Hmwe SS; Shimada N; Kato K; Ide T; Torimura T; Kumada T; Toyoda H; Tsubota A; Takaguchi K; Wakita T; Tanaka Y
PLoS One; 2017; 12(1):e0170667. PubMed ID: 28118381
[TBL] [Abstract][Full Text] [Related]
4. Performance characteristics of the COBAS Ampliprep/COBAS TaqMan v2.0 and the Abbott RealTime hepatitis C assays - implications for response-guided therapy in genotype 1 infections.
Taylor N; Haschke-Becher E; Greil R; Strasser M; Oberkofler H
Antivir Ther; 2014; 19(5):449-54. PubMed ID: 24430620
[TBL] [Abstract][Full Text] [Related]
5. Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir.
Maasoumy B; Cobb B; Bremer B; Luk K; Halfon P; Aslam S; Manns MP; Cornberg M; Wedemeyer H
Aliment Pharmacol Ther; 2014 Jan; 39(1):85-92. PubMed ID: 24206524
[TBL] [Abstract][Full Text] [Related]
6. Can the Abbott RealTime hepatitis C virus assay be used to predict therapeutic outcomes in hepatitis C virus-infected patients undergoing triple therapy?
Ikeda H; Okuse C; Watanabe T; Matsumoto N; Matsunaga K; Shigefuku R; Hattori N; Hiraishi T; Fukuda Y; Noguchi Y; Ishii T; Shima J; Nakahara K; Yamamoto H; Yasuda H; Yotsuyanagi H; Koike K; Itoh F; Suzuki M
Turk J Gastroenterol; 2016 Mar; 27(2):165-72. PubMed ID: 27015621
[TBL] [Abstract][Full Text] [Related]
7. Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: a comparison of two real-time PCR assays.
Ogawa E; Furusyo N; Murata M; Toyoda K; Eiraku K; Shimizu M; Harada Y; Mitsumoto F; Takayama K; Okada K; Kainuma M; Hayashi J
Antiviral Res; 2013 Aug; 99(2):119-24. PubMed ID: 23684903
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients.
Braun DL; Rauch A; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Metzner KJ; Böni J; Weber R; Fehr J
HIV Med; 2014 Nov; 15(10):625-30. PubMed ID: 24894776
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection.
Vermehren J; Aghemo A; Falconer K; Susser S; Lunghi G; Zeuzem S; Colombo M; Weiland O; Sarrazin C
J Hepatol; 2014 May; 60(5):913-9. PubMed ID: 24424305
[TBL] [Abstract][Full Text] [Related]
10. Predictive variables of sustained virological response after early discontinuation of triple therapy with telaprevir for genotype-1 HCV infection.
Acero Fernández D; Morillas Cunill R; Ferri Iglesias MJ; Torras Collell X; Vergara Gómez M; Zaragoza Velasco N; López Nuñez C; Forné Bardera M; Delgado Gómez M; Barenys Lacha M; Torres Salinas M; Villar Fernández M; Durández Lázaro R; Mariño Mendez Z
Gastroenterol Hepatol; 2016; 39(6):377-84. PubMed ID: 26614733
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of advanced fibrosis measured by transient elastography after hepatitis C virus protease inhibitor-based triple therapy.
Sáez-Royuela F; Linares P; Cervera LA; Almohalla C; Jorquera F; Lorenzo S; García I; Karpman G; Badia E; Vallecillo MA; Moncada A; Calvo S; Olcoz JL;
Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):305-12. PubMed ID: 26636405
[TBL] [Abstract][Full Text] [Related]
12. HCV RNA quantification with different assays: implications for protease-inhibitor-based response-guided therapy.
Fevery B; Susser S; Lenz O; Cloherty G; Perner D; Picchio G; Sarrazin C
Antivir Ther; 2014; 19(6):559-67. PubMed ID: 24584086
[TBL] [Abstract][Full Text] [Related]
13. Comparison of on-treatment HCV RNA during direct antiviral therapy using two different COBAS TaqMan HCV assays.
Vermehren J; Bourlière M; Pol S; Marcellin P; Hyland RH; Jiang D; Brainard DM; Zeuzem S; Welzel TM
J Clin Virol; 2017 Apr; 89():51-56. PubMed ID: 28259054
[TBL] [Abstract][Full Text] [Related]
14. Multicentric performance analysis of HCV quantification assays and its potential relevance for HCV treatment.
Wiesmann F; Naeth G; Berger A; Hirsch HH; Regenass S; Ross RS; Sarrazin C; Wedemeyer H; Knechten H; Braun P
Med Microbiol Immunol; 2016 Jun; 205(3):263-8. PubMed ID: 26666643
[TBL] [Abstract][Full Text] [Related]
15. Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients.
Baleriola C; Rawlinson WD; Dore GJ; Chaverot S; Stelzer-Braid S; Yoshihara M; Crawford D; Sievert W; McCaughan G; Weltman M; Cheng W; Rizkalla B; Dubois D; Thommes J; Roberts S
Antivir Ther; 2011; 16(2):173-80. PubMed ID: 21447866
[TBL] [Abstract][Full Text] [Related]
16. Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study.
Bailly F; Virlogeux V; Dufour C; Pradat P; Hézode C; Larrey D; Alric L; Samuel D; Bourlière M; Métivier S; Zarski JP; Fontaine H; Loustaud-Ratti V; Serfaty L; Bronowicki JP; Carrat F; Zoulim F;
Clin Res Hepatol Gastroenterol; 2015 Sep; 39(4):443-50. PubMed ID: 25636238
[TBL] [Abstract][Full Text] [Related]
17. An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-infected patients by use of the Abbott RealTime HCV RNA assay.
Sarrazin C; Dierynck I; Cloherty G; Ghys A; Janssen K; Luo D; Witek J; Buti M; Picchio G; De Meyer S
J Clin Microbiol; 2015 Apr; 53(4):1264-9. PubMed ID: 25653396
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis.
Bruno S; Vierling JM; Esteban R; Nyberg LM; Tanno H; Goodman Z; Poordad F; Bacon B; Gottesdiener K; Pedicone LD; Albrecht JK; Brass CA; Thompson S; Burroughs MH
J Hepatol; 2013 Mar; 58(3):479-87. PubMed ID: 23183529
[TBL] [Abstract][Full Text] [Related]
19. Clinical performances of two real-time PCR assays and bDNA/TMA to early monitor treatment outcome in patients with chronic hepatitis C.
Martinot-Peignoux M; Khiri H; Leclere L; Maylin S; Marcellin P; Halfon P
J Clin Virol; 2009 Nov; 46(3):216-21. PubMed ID: 19748822
[TBL] [Abstract][Full Text] [Related]
20. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
